Skip to search formSkip to main contentSkip to account menu

cabazitaxel

Known as: 1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-{[(tertbutoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate], 4-acetoxy-13-((3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate, Cabazitaxelum 
A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes… 
National Institutes of Health

Related topics

Related topics

10 relations
1.5 ML cabazitaxel 40 MG/ML Injection1.5 ML cabazitaxel 40 MG/ML Injection [Jevtana]ApoptosisMicrotubule Process

Narrower (3)

JevtanaTXD 258XRP6258

Broader (1)

Taxoids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Chemical Derivatization of the Anticancer Agent Cabazitaxel Using a Polyunsaturated Fatty Acid for Safe Drug Delivery In Vivo.
The utilization of nonionic surfactants is a practical way to formulate hydrophobic chemotherapeutics, facilitating the clinical… 
2017
2017
Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
Recently, an increase in the incidence of severe forms of prostate cancer, in particular castration-resistant prostate cancer… 
2017
2017
Evaluation of cabazitaxel's toxicity and tolerance: AC Camargo Cancer Center experience.
e566Background: Cabazitaxel is an approved second-line treatment in metastatic castration-resistant prostate cancer therapy with… 
2016
2016
Real-world experience of therapeutic sequencing and time to first anticancer intervention (ACI) following sipuleucel-T (sip-T): Initial data from the PROCEED registry.
194 Background: Sip-T is an autologous immunotherapy approved for asymptomatic or minimally symptomatic metastatic castration… 
2016
2016
Phase II study of weekly cabazitaxel for ‘unfit’ metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. Circulating tumour cell (CTC) analysis…
(19-0%), and anorexia (30-3%). Neither grade IV diarrhea nor febrile neutropeniawere observed. Nineteen of 32 pts (59%) had early… 
2014
2014
Development and Validation of a Stability-Indicating Liquid Chromatographic Method for the Assay of Cabazitaxel
A validated stability-indicating high-performance liquid chromatographic technique was developed for the determination of… 
2013
2013
Interim safety analysis of a compassionate-use program (CUP) and early-access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastatic castration-resistant…
5055 Background: Cbz + P provides a significant survival benefit vs mitoxantrone + P in pts with mCRPC (Phase III TROPIC study… 
2012
2012
Comparison of second-line treatments in patients with castration-resistant prostate cancer with PSA relapse after or during docetaxel chemotherapy.
243 Background: Docetaxel was the first agent with a proven survival benefit and improved quality of life in patients with… 
2011
2011
Prostate cancer: Abiraterone increases overall survival in men with castration-resistant prostate cancer
Prostate cancer: Abiraterone increases overall survival in men with castration-resistant prostate cancer 
1975
1975
[Studies on the constituents of the aerial parts of Dioscorea tenuipes Franch. et Savat II. Diotigenin 4-acetate and the corresponding furostanol glycoside (author's transl)].